New hope for tough brain tumors? drug trial targets meningioma that Won't quit

NCT ID NCT05023018

Recruiting now Disease control Sponsor: Neonc Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 29 times

Summary

This study tests a drug called NEO100 in people with a fast-growing type of brain tumor (high-grade meningioma) that remains after surgery or has come back. About 30 participants will take NEO100 four times a day in 28-day cycles. The goal is to see if the drug can stop the tumor from growing and to check its safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Baylor Scott and White
RECRUITING

Dallas, Texas, 75246, United States

Contact
Saint John Cancer Institute
RECRUITING

Santa Monica, California, 90404, United States

Contact
University of Southern California
RECRUITING

Los Angeles, California, 90033, United States

Contact

Conditions

Explore the condition pages connected to this study.

RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA